Health and Healthcare

iShares Biotechnology ETF : IBB

All iShares Biotechnology ETF Articles

65 Articles

Chris Lange | Jan 3, 2020 at 11:15 AM EST

The Top Biotech ETFs to Watch in 2020

On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes…

Chris Lange | Jun 18, 2019 at 11:57 AM EDT

Tuesday’s Top BioPharma Movers Deviating from the Market

24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each…

Chris Lange | May 14, 2019 at 9:38 AM EDT

The Best Biotech ETFs to Buy Ahead of ASCO

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical…

Chris Lange | Apr 25, 2019 at 9:45 AM EDT

The Top 10 Biotechs of 2019

Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health…

Jon C. Ogg | Apr 24, 2019 at 12:55 PM EDT

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top…

Jon C. Ogg | Oct 15, 2018 at 11:45 AM EDT

How Wall Street Is Looking at Q3 Earnings Season, Sector by Sector

24/7 Wall St. has come up with its own view on earnings season by sector, along with relative performance on…

Chris Lange | Sep 11, 2018 at 10:55 AM EDT

Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the…

Jon C. Ogg | Jan 27, 2018 at 1:25 PM EST

6 Speculative Biotech Stocks With 50% to 250% Potential Upside

This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and…

Chris Lange | Jan 5, 2018 at 11:15 AM EST

Meet Merrill Lynch’s Top Biotech Picks for 2018

Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and…

Chris Lange | Jul 12, 2017 at 1:25 PM EDT

Merrill Lynch’s Top 4 Internet Stocks for the Second Half of 2017

Merrill Lynch singled out a group in the tech sector that the firm believes will outperform going forward -- specifically,…

Chris Lange | Jul 11, 2017 at 12:10 PM EDT

Meet Jefferies Top 12 Picks in the Roaring Biotech Industry

The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's…

Trey Thoelcke | Dec 30, 2016 at 11:15 AM EST

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.

Jon C. Ogg | Dec 7, 2016 at 12:40 PM EST

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

Trump told Time that he wants to lower drug prices, a move that has hit the drug and biotech segments…

Chris Lange | Aug 9, 2016 at 11:55 AM EDT

Why We Could Expect a Zika Rally in These Stocks

We know that the broad markets work on the basis of greed and fear, but we have to ask ourselves…

Trey Thoelcke | May 26, 2016 at 9:35 AM EDT

Capital Infusions Are More Evidence of a Biotech Turnaround

Here are four biotech companies that have just either closed fresh financing rounds or issued IPOs that exceeded price expectations.

1 2 3 4 5

iShares Biotechnology ETF : IBB

All iShares Biotechnology ETF Articles

The Top Biotech ETFs to Watch in 2020

Tuesday’s Top BioPharma Movers Deviating from the Market

The Best Biotech ETFs to Buy Ahead of ASCO

The Top 10 Biotechs of 2019

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

How Wall Street Is Looking at Q3 Earnings Season, Sector by Sector

Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

6 Speculative Biotech Stocks With 50% to 250% Potential Upside

Meet Merrill Lynch’s Top Biotech Picks for 2018

Merrill Lynch’s Top 4 Internet Stocks for the Second Half of 2017

Meet Jefferies Top 12 Picks in the Roaring Biotech Industry

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

Why We Could Expect a Zika Rally in These Stocks

Capital Infusions Are More Evidence of a Biotech Turnaround

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

iShares Biotechnology ETF : IBB

All iShares Biotechnology ETF Articles

The Top Biotech ETFs to Watch in 2020

Tuesday’s Top BioPharma Movers Deviating from the Market

The Best Biotech ETFs to Buy Ahead of ASCO

The Top 10 Biotechs of 2019

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

How Wall Street Is Looking at Q3 Earnings Season, Sector by Sector

Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

6 Speculative Biotech Stocks With 50% to 250% Potential Upside

Meet Merrill Lynch’s Top Biotech Picks for 2018

Merrill Lynch’s Top 4 Internet Stocks for the Second Half of 2017

Meet Jefferies Top 12 Picks in the Roaring Biotech Industry

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

Why We Could Expect a Zika Rally in These Stocks

Capital Infusions Are More Evidence of a Biotech Turnaround

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

Featured Reads

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income